Financial Architects (New Jersey)’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Financial Architects (New Jersey)’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,000	Closed	-$1K	–	1548
2016 Q3	$1K	Buy	+1,000	New	+$19.5K	﹤0.01%	1433

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Financial Architects (New Jersey)'s HZNP Position: Q3 2018 in Review

Financial Architects (New Jersey) sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2018, closing a stake of 600 shares — an estimated $10K sold.

Financial Architects (New Jersey) first reported a position in HZNP in Q2 2015 and held it in 8 quarters. The position peaked at $12K in Q4 2016. 221 funds tracked by Wall St. Rank hold HZNP as of Q3 2018.

Financial Architects (New Jersey) reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2018 after selling out during the quarter.
Financial Architects (New Jersey) sold 600 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2018, an estimated $10K.
Financial Architects (New Jersey) first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2015 and held it in 8 quarters.
Financial Architects (New Jersey)'s Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $12K in Q4 2016.
221 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2018.

Based on Financial Architects (New Jersey)'s 13F filing for Q3 2018, filed 29 Oct 2018.